The debate highlighted broad cellular toxicity of existing HSP inhibitors but did not resolve how to engineer selectivity for tau-associated chaperones. This structure-activity relationship gap prevents rational drug design.
Source: Debate session sess_SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd (Analysis: SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd)
Small molecules that competitively displace tau-stabilizing immunophilins (FKBP51) from HSP90 while recruiting tau-destabilizing co-chaperones (FKBP52), reprogramming HSP90 complexes from tau-protective to tau-degrading without inhibiting HSP90's essential functions.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMID5 mediumValidation: 42%5 supporting / 1 opposing
✓For(5)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
MECH 6CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Modulating FKBP5/FKBP51 and autophagy lowers HTT (…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-10 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Novel Therapeutic Hypotheses for HSP70/HSP90 Inhibitor Tau-Selectivity
Hypothesis 1: Allosteric Pocket Exploitation for Tau-Specific HSP90 Modulation
Target: HSP90 C-terminal domain allosteric sites
The minimal structural requirement for tau-selectivity involves targeting previously unexploited allosteric pockets in HSP90's C-terminal domain that are uniquely accessible when HSP90 is bound to tau-containing complexes. Unlike ATP-competitive inhibitors that disrupt all HSP90 functions, allosteric modulators binding to these cryptic sites would selectively destabilize tau-HSP90 intera
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
I'll provide a rigorous critique of each hypothesis based on fundamental principles of protein biochemistry, drug development, and neurobiology. Let me analyze the specific weaknesses, alternative explanations, and experimental approaches needed to falsify these claims.
Hypothesis 1: Allosteric Pocket Exploitation for Tau-Specific HSP90 Modulation
Critical Weaknesses:
Overstated selectivity assumption: The hypothesis assumes HSP90 adopts unique conformations when bound to tau that are fundamentally different from other client proteins. However, HSP90 client binding involves co
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
I'll assess the practical feasibility of these HSP70/HSP90 inhibitor hypotheses from a drug development perspective, focusing on druggability, existing chemical matter, competitive landscape, and development challenges.
Overall Market Context & Competitive Landscape
Current HSP90 Inhibitor Landscape: The HSP90 inhibitor field has seen significant commercial failures despite promising preclinical data:
Geldanamycin derivatives (17-AAG, 17-DMAG): Abandoned due to hepatotoxicity and limited efficacy
Ganetespib (Synta Pharmaceuticals): Failed multiple Phase III trials in lung
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF human iPSC-derived cortical neurons harboring P301L MAPT mutations are treated with a 100 nM concentration of a small molecule designed to competitively displace FKBP51 from HSP90 while preferentially recruiting FKBP52, THEN intracellular soluble tau levels will decrease by ≥40% relative to vehicle-treated cultures within 72 hours, as measured by ELISA of cell lysates normalized to total protein.
pendingconf: 0.65
Expected outcome: Soluble tau concentration will decrease by at least 40% in compound-treated neurons compared to vehicle control at 72 hours post-treatment.
Falsified by: Soluble tau levels do not decrease by at least 40% (e.g., <25% change) or show no significant difference from vehicle control (p > 0.05, Student's t-test), indicating the co-chaperone displacement mechanism does not modulate tau stability.
Method: iPSC-derived cortical neurons from at least 3 independent MAPT P301L lines, treated with compound or 0.1% DMSO vehicle for 72 hours, with soluble tau quantified by Meso Scale Discovery electrochemiluminescence ELISA (TAU kit) normalized to total protein via BCA assay.
IF male 3xTg-AD mice (6 months old) receive daily intraperitoneal injections of a selective FKBP51-displacing/FKBP52-recruiting compound at 10 mg/kg for 28 days, THEN hippocampal insoluble tau aggregates will be reduced by ≥35% compared to vehicle-injected age-matched controls, as measured by Sarkosyl-insoluble fraction Western blot.
pendingconf: 0.55
Expected outcome: Sarkosyl-insoluble tau will be at least 35% lower in compound-treated 3xTg-AD mice relative to vehicle controls after 4 weeks of treatment.
Falsified by: No significant reduction in Sarkosyl-insoluble tau (<20% change) or reduction accompanied by motor impairment, weight loss, or hunching behavior indicating HSP90 essential function inhibition (disqualifying mechanism selectivity).
Method: 3xTg-AD mice (n≥10 per group, males only to control for hormonal variability) receiving compound or 0.5% carboxymethylcellulose vehicle daily for 28 days, with hippocampal tau fractionation and measurement performed blinded to treatment group.